10929 Technology Place, Suite B
San Diego, 92127
United States of America, California
Phone: 858 485 9101
Fax: 858 485 9131
E-Mail: info@sapientdiscovery.comThis e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Description:
Sapient Discovery offers powerful and proven structure-based approach to drug discovery in the identificationn and optimization of leads from protein structures termed, Genes-to-Leads®, combines three technologies the (i) Augmented Homology ModelingTM, (iI) DynaPharmTM based virtual screening, and (iii) X-ray crystallography for rapidly and cost-effectivley identifying novel small molecule inhibitor/antagonist leads and determine the mode of binding such inhibitors/antagonists to protein drug targets.
Augmented Homology ModelingTM: A structural bioinformatics based method to derive highly accurate three-dimensional protein models with proprietary loop building.
DynaPharm™ Technology A rapid lead generation technology for peptide/non-peptide, small molecule drug leads based upon differential three-dimensional structures derived from the dynamic conformations and intrinsic structural differences between drug targets and anti-targets within weeks.
X-ray Crystallography: Experimental approach to solving three-dimensional structures of novel proteins, antibodies, antibody-antigen and protein-small molecule complexes. Cloning, expression, purification, proprietary crystallization methods, structure-determination and refinement have been established at Sapient Discovery. Experienced team in place for using this technique in structure-based drug design and optimization by deriving co-crystal structures of lead compounds.
Fragment Based Lead Discovery: Experimental approach to find lead molecule with confirmation of mechanistic binding. Sapient Discovery has over 10,000 (still growing) unique drug-like fragments with enough synthetic handles, that could be used against novel targets for identifying novel, drug-like, small molecule lead molecules and subsequent optimization.
Lead Optimization with Structural Pharmacogenomics: Sapient Discovery has extensive experience in determining and rank ordering the binding of an inhibitor or drug with its respective target and its associated polymorphisms. Polymorphisms in drug targets arise from mutations that arise due drug exposure and/or genetic variation. Sapient Discovery’s structural pharmacogenomics platform provides a practical way to address the implications of the distribution of polymorphisms by race, gender, and genetic predisposition to disease using which potential new drugs are estimated to work for the largest fraction of the patient population.